OR 97331, USA Trilostane, a competitive inhibitor of 3\g=b\-hydroxysteroiddehydrogenase, was administered intravenously to pregnant mares (n = 3) between day 277 and day 282 of gestation to determine its effect on the progestin milieu. In addition, placental tissue from mares at mid-gestation (150\p=n-\300days) (n = 4) were exposed to either deuterium-labelled pregnenolone alone or deuterium-labelled pregnenolone and trilostane to examine the effect of trilostane on placental metabolism of pregnenolone. Blood samples were collected from indwelling jugular catheters at frequent intervals for 48 h after infusion. Both plasma samples and incubation media were quantitatively analysed, after solid phase extraction and steroid derivitization, for concentrations of eight different progestin metabolites using gas chromatography and mass spectrometry. Trilostane infusion differentially affected the progestin milieu in vivo without inducing abortion. Forty-five minutes after infusion, maternal plasma concentrations of pregnenolone, 5-pregnene-3\g=b\,20\g=b\-diol,5\ g=a\-pregnane\x=req-\ 3\g=b\,20\g=b\-di ol and 3\g=b\-hydroxy-5\g=a\-pregnan-20-one increased (P < 0.05) and remained high for 37 h. Concentrations of 5\g=a\-pregnane-3,20-dione,20\g=a\-hydroxy-5\g=a\-pregnan-3-one and 5\g=a\-pregnane-3\g=b\,20\g=a\-diol decreased 15 min after infusion (P < 0.05), yet 1.5 h after infusion, concentrations had increased and remained high until 37 h after infusion. Trilostane inhibited the conversion of pregnenolone to progesterone in vitro (P < 0.001) while mediating an increase (P < 0.05) in concentrations of 5\g=a\-pregnane-3,20-dione and 3\g=b\-hydroxy-5\g=a\-pregnan-20-one. These observations demonstrate that the pregnant mare possesses unique steroid hormone metabolic activity and suggests that another steroid, perhaps 5\g=a\-pregnane-3,20-dione and not progesterone, is the important steroid precursor for the other progestin metabolites found in circulating plasma.
Introduction
The mare possesses unique steroid hormone metabolic activity during mid-and late-gestation. In (Holtan et al, 1991) . In addition, the mare is unusual in that ovariectomy as early as at day 50 of gestation has no adverse effect on pregnancy maintenance (Holtan et al, 1979; Knowles et al, 1994) indicating that pregnancy is maintained henceforth by an extra-luteal source of progestin. One progestin metabolite, , is detectable in the peripheral circulation as early as day 10 (Atkins et al, 1976 ) and concentrations of other metabolites increase throughout pregnancy (Holtan et al, 1975) . Another progestin metabolite, 20a-hydroxy-5a-pregnan-3-one (20 -5 ) , as identified with gas chromatography/mass spectrometry (GC/MS), can reach con¬ centrations of pg ml"1 near parturition, (Holtan et al, 1991) .
The systematic names, abbreviations and structural details of the progestins that are discussed throughout this text, are given in Table I .
In common with other species, the equine placenta contains 3ß-hydroxysteroid-dehydrogenase (3ß-HSD) activity; the placenta metabolizes pregnenolone to progesterone (Ainsworth and Ryan, 1969; Schutzer and Holtan, 1996) . It has thus been suggested that maintenance of pregnancy in mares is controlled primarily by progestins of a placental source (Moss et al, 1979) . To examine this possibility, Fowden and Silver (1987) 3ß-hydroxy-5a-pregnan-20-one 3ß-5 ß-OH = 20a-hydroxy-5a-pregnan-3-one
inhibitor in vivo (Schane et al, 1979; Creange et al, 1981; Taylor et al, 1982; Martin et al, 1987; Crooij et al, 1988) .
Likewise, inhibition of 3ß-HSD in vitro stopped the conversion of pregnenolone to progesterone in dispersed sheep placental cells (Power and Challis, 1987) .
It is important to recognize that Fowden and Silver (1987) Trilostane, a 3ß-HSD competitive inhibitor similar in function to epostane (Potts et al, 1978; Ledger et al, 1985) , Schutzer and Holtan (1996) (1991) . Basic preparation involved internal standard fortification of plasma samples with D4-progestins (D4-5a-DHP, D4-pregnenolone, D4-3ß-5a and D4-5a-pregnane-3ß,20ß-diol (D4-ßß-diol)) pre¬ pared as described by Dehennin et al (1980) (Fig. 2) . However, concentrations of 5a-DHP, 20a-5a, and 5a-pregnane-3ß,20a-diol (ß -diol) initially decreased, but 2 h after the infusion had increased.
Average values for pregnenolone ( Fig. 2; inset) increased nearly tenfold (P < 0.001) 30 min after the infusion, but steadily decreased over time until 37 h after infusion when no differ¬ ence (P> 0.05) from pre-sampling was detected (Fig. 1) . Since pregnenolone-ßß was not detected in plasma before the infusion ( Fig. 2; inset) , the effect of trilostane cannot be determined by comparison with pre-sample concentrations. However, immediately after infusion the average absolute concentration of pregnenolone-ßß in plasma was 24.9 ± 4.6 ng ml~1 (Fig. 2) , which steadily decreased over time until 5 h after infusion when plasma pregnenolone-ßß became undetectable (Fig. 1) . Forty-five minutes after trilostane infusion, 3ß-5 values were higher (P<0.05) than pre-sample concentrations ( Fig. 2) and remained raised up to 37 h after the infusion (Fig. 1) . Values of ßß-diol were higher than pre-sample concen¬ trations 30 min after the infusion (Fig. 2 ) and remained raised (P< 0.05) until 37 h after infusion (Fig. 1) .
The changes in progestins 5ct-DHP, 20 -5 and ßa-diol were all similar after treatment. The values reached an observed nadir (P< 0.01) 15 min after infusion (Fig. 2) Fig. 1 ). Likewise 20 -5 values reached an observed apex 6 h after infusion (P = 0.0002; Fig. 2 ) and then decreased (Fig. 1) . Values for ß -diol reached an observed maximum 3 h after infusion (P = 0.009; Fig. 2 ) and then decreased.
There was no effect (P> 0.1; data not shown) of vehicle on the concentrations of any of the progestins in control mares.
All three mares spontaneously delivered healthy foals within acceptable gestation periods.
Experiments in vitro
Trilostane significantly reduced (P< 0.0001) the placental conversion of D4-pregnenolone to D4-progesterone (Fig. 3) while stimulating an increase (P < 0.05) in the production of D4-5a-DHP and D4-3ß-5rx. In D4-pregnenolone controls, 63.4 + 8.2% of D4-pregnenolone was converted to D4-progesterone, while in the presence of trilostane, only 2.5 ± 0.6% was converted to D4-progesterone. Although only small amounts of D4-5a-DHP (0.2 ± 0.1%) and D4-3ß-5ci
(1.5 + 0.5%) were detected in D4-pregnenolone control incu¬ bations, the increases seen after addition of trilostane represent 10-and 1.5-fold increases (P < 0.05), respectively, compared with controls. placenta, endometrium or in both locations that is yet to be characterized. Silver (1994) suggested that 5a-reductase could also metabolize pregnenolone directly to 3ß-5 . However, empirical evidence for the conversion of pregnenolone to 3ß-5 is circumstantial. When D4-pregnenolone is infused into pregnant mares, substantial quantities of D4-3ß-5a are detected. Likewise, in placental tissue cultures incubated with D4-pregnenolone, one of the progestins found in quantity is D4-3ß-5a. Finally, the presence of a placenta is necessary for the conversion of pregnenolone to 3ß-5 ; when pregnenolone is infused into either pregnant or nonpregnant mares, no 3ß-5 is detected in the nonpregnant animals, while there is an injection-mediated increase in 3ß-5 in pregnant mares (Schutzer and Holtan, 1996) . The pregnant mare also possesses other unusual metabolic processes. Schutzer and Holtan (1996) found that 3ß-5 can be oxidized to 5a-DHP in vivo and in vitro. Consequently, there seem to be two different metabolic pathways to produce 5a-DHP -one using the classic pathway, in which pregnenolone is converted to progesterone through 3ß-HSD, and the other using 5a-reductase, in which pregnenolone is converted to 3ß-5 . Both progesterone and 3ß-5 may be directly metabolized to 5a-DHP through 5a-reductase or 3-oxidase, respectively. A proposed progestin metabolic pathway is presented (Fig. 4) .
Discussion
Results from trilostane treatment both in vivo and in vitro in this study support the presence of this alternative metabolic pathway. Although plasma concentrations of pregnenolone increase nearly ten times as a result of 3ß-HSD inhibition, results suggest differential metabolism of pregnenolone. Clearly, the immediate increase in plasma pregnenolone-ßß is a result of a 20ß-reductase activity on pregnenolone while the subsequent increase in plasma ßß-diol can be explained with 5a-reductase activity on pregnenolone-ßß. The increase in plasma 3ß-5 can be explained by direct 5a-reductase activity on pregnenolone itself. The Progesterone is not detected in maternal circulation, in uterine venous or in umbilical artery blood after 220 days of gestation, and 5a-DHP is undetectable in the umbilical artery (Holtan et al, 1991) . It is possible that fetally synthesized progestins, which may not be reflected in maternal blood, locally affect the uterus thereby maintaining pregnancy. However, trilostane can cross the placenta and enter the fetal circulation, consequently affecting fetal 3ß-HSD in the same manner as it affects maternal 3ß-HSD. Also, both Hamon et al (1991) and Silver (1994) the main goal of this experiment was not to examine abortion, but to examine steroidal alterations induced by trilostane. However, abortion was induced when pregnant rhesus mon¬ keys, rats, sheep, swine, cows or humans were exposed to dosages similar to or lower than that used in this study with a 3ß-HSD competitive inhibitor in vivo (Schane et al, 1979;  Creange et al, 1981; Taylor et al, 1982; Martin et al, 1987; Crooij et al, 1988) . Therefore, 5a-DHP, and not progesterone, may be the important substrate for formation of the 5a-pregnanes found in maternal circulation and could prove to be the compound responsible for pregnancy maintenance. It was suggested that 5a-DHP was of some importance. Hamon et al. (1991) indicated that 5a-DHP could exert central effects in the fetus or mare, and Silver (1994) proposed that 5a-DHP could maintain the myometrium in a quiescent state and might therefore possess progesfagenic bioactivity. 
